Merck KGaA to Acquire Bio-Techne in $11.3 Billion All-Cash Deal
Merck KGaA has agreed to acquire Bio-Techne (TECH) for $11.3 billion in an all-cash deal, representing a ~24% premium. The acquisition strengthens Merck's life sciences and diagnostics business, with closure expected in H1 2027.
Key Numbers
Merck KGaA (MRK) announced Thursday it has entered into a definitive agreement to acquire Bio-Techne (TECH) in an all-cash transaction valued at $11.3 billion, or $116.50 per share. The offer represents a premium of approximately 24% over Bio-Techne's closing price on June 24, 2026. The transaction is expected to close in the first half of 2027, subject to regulatory approvals.
Deal Details
| Item | Detail |
|---|---|
| Total Value | $11.3 billion |
| Per Share Price | $116.50 cash |
| Premium | ~24% over prior close |
| Payment Method | All cash |
| Expected Close | H1 2027 |
Rationale
Merck aims to bolster its life sciences and diagnostics segment, particularly in recombinant proteins, reagents, and analytical instruments. The combined business will have over $4 billion in annual revenue. The acquisition also expands Merck's presence in high-growth areas like regenerative medicine and gene therapy.
Regulatory Hurdles
The deal requires approvals from U.S. CFIUS, EU antitrust authorities, and China's regulators. Potential divestitures may be needed to address competition concerns in the laboratory reagents market.
Stock Impact
Bio-Techne shares are expected to trade near the offer price, while Merck shares may face slight pressure due to the acquisition cost. Analysts will monitor Merck's ability to achieve the stated synergies of approximately $300 million annually by year three post-close.
Frequently Asked Questions
Found this useful? Share it